MedPath

Community-and Primary Care-based Intervention Linked With mObile Technology for HTN Control in Nepal

Not Applicable
Not yet recruiting
Conditions
Hypertension
Registration Number
NCT07076134
Lead Sponsor
Duke Kunshan University
Brief Summary

The clinical trial aims to evaluate whether a community and primary care-based intervention linked with mobile technology (CoPILOT) is acceptable, effective, cost-effective, sustainable, and scalable in improving hypertension (HTN) control among individuals aged 30 to 70 in Nepal. The primary research questions include:

Is the use of the application by Frontline Health Workers (FLHWs) and Female Community Health Volunteers (FCHVs) feasible and acceptable? Can FCHVs equipped with mHealth technology effectively increase the linkage of individuals with elevated blood pressure (BP) to health facilities? Does a mobile-based lifestyle intervention reduce or control BP? Can adherence to prescribed HTN treatments be improved among patients through this intervention?

Detailed Description

The researcher will compare the intervention and control groups to assess changes in BP, quality of life (QoL), body mass index (BMI), medication adherence, and linkage to care.

Participants in the intervention group will:

Attend bi-monthly meetings conducted by FCHVs for BP measurement, facilitated through the mobile application.

Receive healthy lifestyle awareness guidance provided by FCHVs via the mobile app and supplemented with text message reminders.

Visit nearby health facilities for monthly follow up.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
520
Inclusion Criteria
  • Hypertensive patient's should be in the range of 30 to 70 years old living in selected communities with HTN (systolic BP ≥ 130 mmHg or diastolic ≥ 85 mmHg or taking antihypertensive medication)
  • They should have been diagnosed previously and under medication.
  • They should agree to the informed consent
  • FCHVs should be working for the selected communities and agree to the informed consent
  • FLHWs should work for the health facilities in selected communities and agree to the informed consent.
Exclusion Criteria
  • Participants who are not able to respond during the data collection period.
  • Participants who are out of municipality during the data collection period.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in blood pressure (mmHg)Three months intervention

Change in systolic and diastolic blood pressure (mmHg) among hypertensive patients in the intervention group will be measured using a validated digital blood pressure monitor at baseline and endline. The outcome will be reported as the mean change in systolic and diastolic blood pressure.

Secondary Outcome Measures
NameTimeMethod
Change in body weight(kg)During baseline and endline (3 months intervention period)

Weight will be measured in kilograms using a weighing scale at health posts by healthcare providers or by FCHVs during group meetings. The measurements will be recorded in the application and later analyzed to assess changes in body weight.

Change in quality of life as measured by EuroQol Visual Analogue Scale (EQ VAS)Three months intervention period

Quality of life will be assessed using the EuroQol Visual Analogue Scale (EQ VAS), administered by the study team at baseline and endline. Participants will rate their overall health on a vertical visual analogue scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state), and changes in these scores will be used to evaluate improvements in health-related quality of life.

Height (meters)At baseline or endline (3 months intervention period)

FLHWs will measure the height (in meters) by using stadiometer at health posts. They will enter the data in the application.

Change in body mass index (BMI) (kg/m²)Three months intervention period

Body Mass Index (BMI) will be calculated using the formula BMI = weight (kg) / height² (m²). The BMI values will be derived from the collected data and analyzed to assess changes.

Change in perceived empowerment among FCHVs and FLHWs as assessed through structured qualitative interviewsThree months intervention period

Empowerment will be assessed through qualitative semi-structured interviews conducted with FCHVs and FLHWs at both baseline and endline. Interview questions will explore changes in core dimensions of empowerment, including knowledge, confidence, and role perception, in relation to the hypertension mHealth intervention. Interviews will be audio-recorded, transcribed verbatim, and analyzed using thematic analysis. The outcome will be reported as a summary of key themes and illustrative quotes that reflect perceived changes in empowerment over the 3-month intervention period.

Change in antihypertensive medication adherence as measured by the Morisky Green Levine Medication Adherence Scale (MGLS)Three months intervention period

Medication adherence will be assessed using the Morisky Green Levine Medication Adherence Scale (MGLS), administered by the study team at baseline and endline. The MGLS is a 4-item self-report scale that assesses medication-taking behavior, with each item scored 1 for "No" and 0 for "Yes." Total scores range from 0 to 4, with higher scores indicating better adherence. The outcome will be reported as the change in MGLS total score over the 3-month intervention period.

Trial Locations

Locations (1)

Namobuddha municipality

🇳🇵

Namobuddha, Kavrepalanchowk, Nepal

Namobuddha municipality
🇳🇵Namobuddha, Kavrepalanchowk, Nepal
Karma Lama
Contact
9851255760
namobuddhahs@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.